Year: 2025
Type: article
Abstract: In this issue of Blood, Li et al 1 report that tropifexor, an experimental farnesoid X receptor (FXR) agonist, has the potential to improve obesityassociated impairment of fibrinolysis through modulation of hepatic plasminogen activator inhibitor-1 (PAI-1) expression.
Source: Blood
Author: Alan J. Stewart
Institution: University of St Andrews
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4416186505